All In Biotech

Free tool

FAERS Monitor: Cosela

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214200 or its brand name (Cosela, Trilaciclib Dihydrochloride). Reports on generic versions are filed under their own applications.

Reports

244

Serious

136

56% of reports

Hospitalization

80

Death reported

25

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • myelosuppression37
  • off label use27
  • dyspnoea19
  • white blood cell count decreased19
  • platelet count decreased18
  • death16
  • pneumonia15
  • anaemia14
  • performance status decreased14
  • fatigue13
  • nausea13
  • infection12
  • chest discomfort11
  • haemorrhage11
  • infusion site pain11

Reports by year received

View as table
YearReports
20181
202128
202267
202363
202418
202550
202617

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,915 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
performance status decreasedSignal14259.4155.93,341
myelosuppressionSignal3788.665.93,121
infusion site painSignal1173.641.3717
white blood cell count decreasedSignal1915.19.8238
platelet count decreasedSignal1814.69.3215
chest discomfortSignal119.35.273
haemorrhageSignal119.15.171
infectionSignal127.14.158
anaemiaSignal146.33.858
pneumoniaSignal154.02.431
dyspnoeaSignal192.91.922
off label useSignal272.71.927
death161.61.03
fatigue131.40.81
nausea131.40.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.